Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Atorvastatin on Lomitapide PK
NCT02080455Phase 1Completed
- Sponsor
- Aegerion Pharmaceuticals
- Start
- Jan 2014
- Primary completion
- Mar 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of lomitapide in homozygous familial hypercholesterolemia (HoFH) (2 arms), sponsored by Aegerion Pharmaceuticals. Primary endpoints: Maximum Plasma Concentration at 168 hours, Time to Maximum Plasma Concentration at 168 hours and 3 more. Started Jan 2014; status: completed.
02
Drugs
lomitapide
03
Conditions
homozygous familial hypercholesterolemia (HoFH)
Beyond the preview
Go deeper on NCT02080455.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02080455.